Catalyst
Slingshot members are tracking this event:
Tesaro's (TSRO) Rolapitant IV Rejected by FDA for the Prevention of Delayed Nausea and Vomiting Associated with Emetogenic Chemotherapy
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| TSRO |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jan 12, 2017
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Rolapitant Iv, Fda, Marketing Application, Rejected, Delayed Nausea, Vomiting, Emetogenic Chemotherapy, Complete Response Letter
